Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver malignancy characterized by the coexistence of both hepatocellular and biliary morphological differentiation. It is thought to represent less than 5% of all primary liver cancers and is associated with a dismal clinical course. Due to its rarity and inherent diagnostic challenges, consensus guidelines for the management of patients with cHCC-CCA are lacking, and treatments are usually extrapolated from HCC or CCA guidelines. This review provides an overview of the main clinical and histo-molecular features of cHCC-CCA, along with its diagnostic and therapeutic challenges. Technological advances have allowed researchers to progressively elucidate cHCC-CCA's unique biology and heterogeneity. Several major questions, however, remain, such as the cHCC-CCA cell of origin. Integration of multi-modal data and use of artificial intelligence provide interesting perspectives to further improve patient management; however, they will need to be carefully assessed and validated. A better definition and understanding of this entity will be key to further planning clinical trials.
Authors
- Shaodian Xu
- Julien Caldéraro (ORCID: https://orcid.org/0000-0002-5370-0807)
Institutions
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Hôpital Albert-Chenevier (FR)
- Institut Mondor de Recherche Biomédicale (FR)
Publication Details
- Journal
- Seminars in Liver Disease
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1055/a-2730-9074
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00